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T
HE FUNCTIONAL AND STRUCTURAL STATE OF THE
pulmonary vascular bed plays a pivotal role in
the presentation and outcome of the child
with congenital cardiovascular disease. It is in the
immediate postoperative period that the child is
most vulnerable to a sudden or sustained increase in
pulmonary vascular resistance. Following surgery
for congenital cardiac disease, pulmonary vascular
reactivity is heightened, and vasospastic stimuluses
may result in sudden increases in pulmonary arterial
pressure and resistance, resulting in acute right-
sided cardiac failure, tricuspid regurgitation, sys-
temic hypotension, myocardial ischaemia, and
increased resistance in the airways. These episodes,
called pulmonary hypertensive crises, may be lethal
events. Mildly stimulating events can precipitate
similar crises, and the crises tend to last longer and
cluster.1,2
The pathophysiology of such events is complex,
and incompletely understood by the analysis or
measurement of a single vasoactive mediator. Post-
operative pulmonary hypertension represents a
complex interplay between the preoperative condi-
tion of the patient, particularly age at repair, type of
lesion, and presence of a syndrome, and the
inevitable disruption in the environment of hor-
mones and vasoactive peptides that results from
cardiac surgery. Important contributors to the
milieu of enhanced vasoconstriction are cardiopul-
monary bypass, hypothermia, and circulatory arrest.
Residual cardiac lesions, and the sequels of the
response to stress, hypoxia, and metabolic and
respiratory acidosis, may all contribute additional
imbalances favouring pulmonary vasoconstriction.
Postoperative sequels such as right and left
ventricular and atrioventricular valvar dysfunction
will be important in determining how well the
postoperative elevation in pulmonary vascular
resistance is tolerated. Currently, dysfunction of
endothelial cells, present preoperatively and exacer-
bated by perioperative influences, is considered a
unifying hypothesis to account for many post-
operative sequels.3–5 Improvements in surgical and
perioperative technique, however, and perhaps most
importantly the trend towards performing surgical
repair early, has resulted in a marked decrease in the
incidence of symptomatic postoperative pulmonary
hypertension in countries with privileged patterns
of referral. The incidence of postoperative pulmon-
ary hypertensive events decreased from 31% in the
period from 1980 through 1984, to 6.8% before the
routine use of inhaled nitric oxide.6 Series reflective
of contemporary practice suggest that pulmonary
hypertension complicates 2.0% of patients under-
going congenital cardiac surgery, with crises occur-
ring in 0.75%.7 The mortality in those suffering a
crisis, nonetheless, remains high, at 20%, and
pulmonary vascular disease is identified as a major
contributor to length of stay in hospital, and the need
for prolonged mechanical ventilation.6–9
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Predicting risk factors for symptomatic
postoperative pulmonary hypertension
It is difficult to predict which patients will
experience pulmonary hypertensive crises, or right
ventricular failure with low cardiac output post-
operatively. Patients who experience crises usually
have reactive pulmonary vascular beds. Patients
dying from pulmonary arterial hypertensive crises
have increased muscularization of the small pul-
monary arterioles without changes of irreversible
pulmonary vascular disease.1 Patients who undergo
surgical repair with fixed elevations of pulmonary
vascular resistance may not experience crises, but are
at risk of right ventricular failure, especially if there
is postoperative deterioration of atrioventricular
valvar regurgitation and right ventricular function.
Most patients with lesions produced by increased
arterial flow to the lungs at high pressure but low
pulmonary vascular resistance will not require
postoperative therapy for pulmonary arterial hyper-
tension.7 There is, therefore, considerable value in
attempting to select high-risk patients for special
monitoring, or even prophylactic therapy. Stratifi-
cation of risk is mainly clinical, because lung biopsy
and cardiac catheterization are not performed
routinely prior to cardiac surgery. Patients with
clinical or echocardiographic signs of an elevated
pulmonary vascular resistance may benefit from
preoperative cardiac catheterization to assess risk
and operability. Preoperative lung biopsy alone has
a limited capacity to define operability compared
with haemodynamic assessments. Patients with
extracardiac syndromes, especially Down’s syn-
drome, seem to be at increased risk of pulmonary
hypertensive events.7 Patients with pulmonary
venous or left atrial hypertension, whether follow-
ing pulmonary venous surgery or from abnormal-
ities of the left heart such as hypoplasia, mitral
regurgitation, or stenosis, have extremely reactive
pulmonary vasculature. In general, for all lesions,
early repair appears to confer benefit on post-
operative pulmonary vascular complications. This
applies to those with common arterial trunk,
atrioventricular septal defect, ventricular septal
defect, and transposition with ventricular septal
defect.7,10,11 Patients with aortic origin of a
pulmonary artery, common arterial trunk, and
functionally univentricular lesions with unrest-
rictive pulmonary blood flow have markedly
reactive pulmonary vascular beds in the post-
operative period, especially if intervention is
delayed beyond the age of 2 months.10,12 All
patients with problematic postoperative pulmonary
hypertension should undergo investigation to
exclude residual or overlooked left-to-right intra-
cardiac shunts. In general, there is consensus that
early repair of uncomplicated left to right shunt
lesions in the first 6 months of life reduces the risk
of postoperative pulmonary hypertension in patients
with high-risk diagnoses. Thus a profile of a high-
risk patient might be a 14-month-old child with
Down’s syndrome, an unbalanced atrioventricular
septal defect, but not sufficiently unbalanced to
preclude biventricular repair. At preoperative car-
diac catheterization, the pulmonary vascular resis-
tance index is calculated at 6.0 Wood units m2.
The patient is reactive to inhaled nitric oxide and
hyperoxia. The lowest pulmonary vascular resistance
index is 1.5 Wood units m2, with a shunt of more
than 5 to 1 from left to right. The child undergoes
repair, and postoperatively there is insufficiency and
stenosis of the newly reconstructed left atrioven-
tricular valve, and regurgitation across the right
atrioventricular valve.
The use of pulmonary arterial catheters
If it is difficult to predict who will develop
symptomatic postoperative pulmonary hyperten-
sion, the question may be asked whether all patients
should have a pulmonary arterial catheter inserted
to monitor pulmonary arterial pressure. The use of
pulmonary arterial lines is associated with low
morbidity, particularly when used in an institution
experienced in their management. The adverse event
associated with short-term insertion of such lines is
the risk of bleeding after removal, especially in the
presence of elevated pulmonary arterial and right
ventricular pressures.13 The risk may be mitigated
by placing the line through the right atrium, or the
muscular right ventricular infundibulum. The
incidence of symptomatic pulmonary arterial hyper-
tension, however, is now so low that it may no
longer be justified to place a line in all patients
undergoing repair of high pressure or high flow
lesions, or both. Pulmonary arterial lines focus the
attention of caregivers on the pulmonary arterial
pressure. This may, paradoxically, delay progress
through the cardiac intensive care unit, as there is a
tendency to react to each fluctuation in pulmonary
arterial pressure. For the evaluation of new post-
operative therapies, nonetheless, whether specific for
the pulmonary vasculature or otherwise, pulmonary
arterial lines are essential to provide data on cardiac
output, as well as for the calculation of pulmonary
vascular resistance. Often the decision to place a
pulmonary arterial line is made by necessity in the
operating room in presence of elevated pulmonary
arterial pressures, with mean pressures greater than
25mmHg or more than 50 to 60% of systemic
pressure, or if there is the need for specific
316 Cardiology in the Young August 2009
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1047951109990175
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 19:48:59, subject to the Cambridge Core terms of use, available at
pulmonary vasodilator therapy to separate from
cardiopulmonary bypass. Echocardiography accu-
rately predicts right ventricular and pulmonary
arterial pressures through interrogation of the
velocities of tricuspid regurgitation and pulmonary
insufficiency. Imaging of the right ventricle and
evaluation of potential residual lesions is also useful.
Echocardiographic assessment in the sick unstable
postoperative patient with limited windows, none-
theless, is operator-dependant, and while echocar-
diographic assessment is extremely valuable, it
may not be feasible in off-hours or during a crisis.
After the crisis has resolved, pulmonary arterial
pressures may be misleadingly normal. Right
ventricular pressure may not predict pulmonary
arterial pressure if there is obstruction of the right
ventricular outflow tract, or in the right or left
pulmonary arteries. Echocardiography, together
with monitoring of mixed venous saturations and
central venous pressures, nonetheless, are powerful
tools in the assessment of pulmonary hypertensive
patients. The use of small implantable devices that
monitor pulmonary arterial pressure have not been
used extensively in this population. If the patient is
at risk for sustained pulmonary hypertension, and
prolonged postoperative therapy is likely, these
devices may have a place in monitoring.
The management of postoperative pulmonary
hypertension
There are no clear measurements of pulmonary
arterial pressure or pulmonary vascular resistance
that indicate a need for postoperative therapy.
Consensus would indicate that patients with post-
operative pulmonary hypertension with mean
arterial pressures greater than 25mmHg, or more
than 50 to 60% of systemic pressure, associated
with signs of low cardiac output or its surrogates,
are concerning and indicative of the need to consider
specific therapy. Prevention of pulmonary hyperten-
sive crises is a worthy goal of treatment, but elusive
because of the difficulty in predicting who will
suffer a crisis, along with the rarity of crises in
contemporary practice.
Management of symptomatic pulmonary hyperten-
sion involves avoiding or mitigating vasoconstrictive
triggers, and the use of pulmonary vascular specific
therapies. It has been observed that pulmonary
hypertensive crises may be triggered by stressful
stimuluses, including tracheal suctioning, pain, and
anxiety. The use of fentanyl at high doses to suppress
the response to stress in neonates undergoing surgery
has been established in randomized controlled
studies.14,15 It has become common practice to use
continuous infusions of fentanly combined with
muscular relaxation through the first postoperative
night. Supplemental doses of fentanyl prior to
endotracheal suctioning will suppress the pulmonary
vasoconstrictor response providing suction is per-
formed without causing hypoxia or hypercarbia.
Hypoxia is a potent pulmonary vasoconstrictor,
and should be avoided in high-risk patients. There
is less evidence to suggest that hyperoxia is as
potent a vasodilator as in the preoperative patient.
Mechanical ventilation with high concentrations of
oxygen for prolonged periods should be avoided.
Avoiding hypoxia is extremely important, and
ventilation with supplemental oxygen is used often
to prevent triggering pulmonary vasoconstriction.
Acidosis, whether respiratory or metabolic, is a
powerful vasoconstrictor, and alkalosis is as effective
a pulmonary vasodilator as inhaled nitric oxide.16,17
Hyperventilation, or the infusion of sodium
bicarbonate, is an extremely useful strategy in the
immediate management of pulmonary hypertensive
crises while more specific strategies are put in place.
There are, however, drawbacks to prolonged induc-
tion of therapeutic alkalosis. The disadvantages of
prolonged high mechanical ventilator settings
include pulmonary barotraumas, and reduction of
cardiac output, especially in the face of poor right
ventricular function. Infusions of sodium bicarbo-
nate decrease cardiac output and cerebral blood flow
and increase central venous pressure and systemic
vascular resistance. Avoiding acidosis is as impor-
tant as avoiding hypoxia to prevent pulmonary
vasoconstriction, and most would advocate a pH of
greater than 7.4 in patients at risk, or 7.5 in
refractory pulmonary arterial hypertension. In
patients with a surgically created right-to-left
‘‘pop off’’ and hypoxemia, some would advocate
adjusting the haemoglobin to a level commensurate
with systemic arterial saturations of oxygen.
Inhaled nitric oxide has become the accepted
therapy for postoperative pulmonary arterial hyper-
tension. Its advantages include the ease of delivery,
minimal side effect profile, and specificity for the
pulmonary vascular bed. Nitric oxide is derived from
endothelial cells, and activates guanylate cyclase to
cause vascular vasodilation through a mechanism
dependent on cyclic guanosine monophosphate.
Nitric oxide is inactivated rapidly by haemoglobin.
If inhaled, it causes selective pulmonary vasodila-
tion because of rapid inactivation by haemoglobin
before transit through the pulmonary vascular bed.
Thus, unlike non-specific pulmonary vasodilators,
nitric oxide decreases the intrapulmonary shunt
fraction, and will often improve systemic arterial
oxygenation.
When inhaled, nitric oxide has been shown in
many studies to be an effective pulmonary vasodilator
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in postoperative patients with congenital cardiac
disease.3,16,18–22 The doses have ranged from 2–80
parts per million.19 There does not appear to be any
clear benefit from doses in excess of 10–20 parts per
million for routine use. It is often forgotten that
the measured levels represent the concentration
at the proximal endotracheal tube, and may not
reflect the dose delivered to the alveolus. Side effects,
such as methaemoglobinemia, are rare with doses less
than 80 parts per million even for prolonged periods.
It is prudent, however, to measure levels of methae-
moglobin daily while nitric oxide is administered.
Commercially available devices for delivery, and
use of ventilators without mechanical bellows, have
reduced concerns with nitric dioxide and issues
surrounding gas scavenging.23,24 Thus, inhaled
nitric oxide may reduce mortality after repair of
atrioventricular septal defects.22 In a randomised
double blind controlled trial, treatment with nitric
oxide reduced pulmonary arterial hypertensive crises
and shortened the time to reach criterions for
extubation. The number of days requiring ventila-
tion, however, were not significantly different,
perhaps in view of the prolonged protocol used for
weaning to avoid rebound pulmonary hyperten-
sion.25 Another randomized and controlled study
failed to show an advantage when nitric oxide was
used against a background of presumably hyperoxic
alkalosis.26
Rebound pulmonary hypertension has been
described upon rapid withdrawal of nitric oxide,
or withdrawal prior to resolution of pulmonary
vascular constriction.27,28 Rebound may result in
considerable hemodynamic instability, ventilatory
difficulty, and hypoxia. It requires reinstitution of
inhaled nitric oxide, or adjunctive therapies such as
hyperoxic alkalosis. The effects can be minimized by
slow weaning, in particular the last 5 parts per
million. The need, however, for prolonged inhala-
tion of nitric oxide may delay tracheal extubation,
and transition to oral or intermittently inhaled
pulmonary vasodilators may be considered at this
point in therapy. A randomized controlled blinded
study has demonstrated that oral sildenafil, an
inhibitor of type 5 phosphodiesterase, given at 0.3
to 0.5mg/kg, results in abolition of rebound, and
facilitates shorter times to extubation and in
intensive care.29 This strategy also may be useful
in transitioning patients to chronic therapy.30
Despite attention to adjunctive measures, and the
use of inhaled nitric oxide, there are patients whose
pulmonary arterial hypertension is refractory to
therapy. Sildenafil given intravenously or orally, and
inhaled iloprost and intravenous prostacyclin, may
be used to augment an insufficient pulmonary
vasodilatory response to inhaled nitric oxide.
Drugs, which augment cardiac output as well as
dilate the pulmonary vascular bed, such as milri-
none, levosimendan, and nesiritide may be useful
adjuncts providing the patient is tolerant of
systemic vasodilation. Vasopressin is a pulmonary
vasodilator and systemic vasoconstrictor, and may
be useful in the management of systemic hypo-
tension associated with pulmonary hypertension.
Strategies to prevent pulmonary hypertension post-
operatively by initiating therapies prior to or during
cardiopulmonary bypass such as citrulline to augment
nitric oxide production, sildenafil to increase cyclic
guanosine monophosphate levels, or endothelin
receptor antagonists to diminish the effects of elevated
endothelin 1 levels, are promising ideas and
potentially fruitful areas of research.31,32
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